With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...
Sarcoidosis is a rare systemic disease that afflicts an estimated 200,000 people in the U.S., more often people who are Black ...
Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...
Cardiac sarcoidosis (CS) was a complication in about 10% of pulmonary sarcoidosis (PS) cases, investigators reported in Respiratory Medicine. The retrospective study assessed the prevalence, incidence ...
The following is a summary of "Respiratory abnormalities in sarcoidosis: physiopathology and early diagnosis using ...
No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study ...
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...
Considering taking supplements to treat sarcoidosis? Below is a list of common natural remedies used to treat or reduce the symptoms of sarcoidosis. Follow the links to read common uses ...
SAN DIEGO - aTyr Pharma, Inc. (NASDAQ: ATYR) reported a narrower-than-expected fourth quarter loss on Wednesday, but shares fell 4.8% in after-hours trading as investors focused on the company’s cash ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback